Last 12 months
Inside the activity.
0 purchase rows · 46 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 7 |
| Dec 2025 | 0 | 9 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 2 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 15 |
| Aug 2026 | 0 | 5 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 11, 2019 Filed Feb 13, 2019 21:20 UTC |
Stamoulis ChristianaEVP & Chief Financial Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 72,809 | $0.00 Strike: $80.21 | $0.00 |
DisclosureSEC source: 0001209191-19-009612 · doc4.xml · derivative · entry 2 Stamoulis Christiana · CIK 0001502917 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,809 Underlying: Common Stock · 72,809 shares Expires 2029-02-11 F2 · derivative.exercise_date: Beginning February 11, 2019, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 21:20 UTC |
Stamoulis ChristianaEVP & Chief Financial Officer
|
GrantCommon Stock | 10,285 | $80.21 | $824,959.85 |
DisclosureSEC source: 0001209191-19-009612 · doc4.xml · nonDerivative · entry 1 Stamoulis Christiana · CIK 0001502917 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,285 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Ms. Christiana Stamoulis's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 21:36 UTC |
SWAIN PAULA JEVP, Human Resources
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $18.32 | $0.00 |
DisclosureSEC source: 0001209191-19-007362 · doc4.xml · derivative · entry 3 SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,782 Underlying: Common Stock · 10,000 shares Expires 2020-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Beginning February 9, 2013, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 21:36 UTC |
SWAIN PAULA JEVP, Human Resources
|
SaleCommon Stock | 10,000 | $81.19 | $811,900.00 |
DisclosureSEC source: 0001209191-19-007362 · doc4.xml · nonDerivative · entry 2 SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,124 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · price: Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated. F3 · price: Represents weighted average sale price. Actual sale prices ranged from $80.69 - $81.59. F4 · balance_after: This includes an aggregate of 5,416 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 21:36 UTC |
SWAIN PAULA JEVP, Human Resources
|
Exercise / conversionCommon Stock | 10,000 | $18.32 | $183,200.00 |
DisclosureSEC source: 0001209191-19-007362 · doc4.xml · nonDerivative · entry 1 SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,124 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 28, 2019 Filed Jan 30, 2019 21:22 UTC |
Flannelly Barry PEVP & General Manager US
|
SaleCommon Stock | 1,000 | $80.00 | $80,000.00 |
DisclosureSEC source: 0001209191-19-006004 · doc4.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,944 F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · balance_after: Includes an aggregate of 5,416 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| January 17, 2019 Filed Jan 22, 2019 23:04 UTC |
Wenqing YaoEVP, Head of Discovery Chem
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 15,354 | $0.00 Strike: $17.79 | $0.00 |
DisclosureSEC source: 0001209191-19-004819 · doc4.xml · derivative · entry 3 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,354 shares Expires 2019-01-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Beginning January 19, 2012, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years. Read SEC document |
| January 17, 2019 Filed Jan 22, 2019 23:04 UTC |
Wenqing YaoEVP, Head of Discovery Chem
|
SaleCommon Stock | 15,354 | $77.61 | $1,191,623.94 |
DisclosureSEC source: 0001209191-19-004819 · doc4.xml · nonDerivative · entry 2 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,409 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · price: Represents weighted average sale price. Actual sale prices ranged from $76.43 to $78.56. F3 · price: Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated. F4 · balance_after: This includes an aggregate of 5,416 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| January 17, 2019 Filed Jan 22, 2019 23:04 UTC |
Wenqing YaoEVP, Head of Discovery Chem
|
Exercise / conversionCommon Stock | 15,354 | $17.79 | $273,147.66 |
DisclosureSEC source: 0001209191-19-004819 · doc4.xml · nonDerivative · entry 1 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,763 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 15, 2019 Filed Jan 17, 2019 21:15 UTC |
Trower PaulPrincipal Accounting Officer
|
Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 5,813 | $0.00 Strike: $17.79 | $0.00 |
DisclosureSEC source: 0001209191-19-004192 · doc4.xml · derivative · entry 3 Trower Paul · CIK 0001642041 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,813 shares Expires 2019-01-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Beginning January 19, 2012, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years Read SEC document |
| January 15, 2019 Filed Jan 17, 2019 21:15 UTC |
Trower PaulPrincipal Accounting Officer
|
SaleCommon Stock | 5,813 | $75.00 | $435,975.00 |
DisclosureSEC source: 0001209191-19-004192 · doc4.xml · nonDerivative · entry 2 Trower Paul · CIK 0001642041 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,900 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · balance_after: This includes an 4,797 aggregate of shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| January 15, 2019 Filed Jan 17, 2019 21:15 UTC |
Trower PaulPrincipal Accounting Officer
|
Exercise / conversionCommon Stock | 5,813 | $17.79 | $103,413.27 |
DisclosureSEC source: 0001209191-19-004192 · doc4.xml · nonDerivative · entry 1 Trower Paul · CIK 0001642041 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,713 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 08, 2019 Filed Jan 10, 2019 21:11 UTC |
Flannelly Barry PEVP & General Manager US
|
SaleCommon Stock | 1,714 | $75.56 | $129,509.84 |
DisclosureSEC source: 0001209191-19-003251 · doc4.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,944 F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · balance_after: Includes an aggregate of 5,416 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| January 07, 2019 Filed Jan 8, 2019 21:46 UTC |
Wenqing YaoEVP, Head of Discovery Chem
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $17.79 | $0.00 |
DisclosureSEC source: 0001209191-19-002811 · doc4.xml · derivative · entry 5 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,354 Underlying: Common Stock · 10,000 shares Expires 2019-01-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Beginning January 19, 2012, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years Read SEC document |
| January 07, 2019 Filed Jan 8, 2019 21:46 UTC |
Wenqing YaoEVP, Head of Discovery Chem
|
Tax withholdingCommon Stock | 808 | $74.21 | $59,961.68 |
DisclosureSEC source: 0001209191-19-002811 · doc4.xml · nonDerivative · entry 3 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,409 F2 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F3 · balance_after: This includes an aggregate of 5,416 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| January 07, 2019 Filed Jan 8, 2019 21:46 UTC |
Wenqing YaoEVP, Head of Discovery Chem
|
SaleCommon Stock | 10,000 | $75.00 | $750,000.00 |
DisclosureSEC source: 0001209191-19-002811 · doc4.xml · nonDerivative · entry 2 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,217 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. Read SEC document |
| January 07, 2019 Filed Jan 8, 2019 21:46 UTC |
Wenqing YaoEVP, Head of Discovery Chem
|
Exercise / conversionCommon Stock | 10,000 | $17.79 | $177,900.00 |
DisclosureSEC source: 0001209191-19-002811 · doc4.xml · nonDerivative · entry 1 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,217 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 07, 2019 Filed Jan 8, 2019 21:37 UTC |
SWAIN PAULA JEVP, Human Resources
|
Tax withholdingCommon Stock | 1,200 | $74.21 | $89,052.00 |
DisclosureSEC source: 0001209191-19-002796 · doc4.xml · nonDerivative · entry 3 SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,124 F2 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F3 · balance_after: This includes an aggregate of 5,416 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| January 07, 2019 Filed Jan 8, 2019 21:42 UTC |
Trower PaulPrincipal Accounting Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 9,187 | $0.00 Strike: $17.79 | $0.00 |
DisclosureSEC source: 0001209191-19-002803 · doc4.xml · derivative · entry 6 Trower Paul · CIK 0001642041 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,187 shares Expires 2019-01-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Beginning January 19, 2012, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years Read SEC document |
| January 07, 2019 Filed Jan 8, 2019 21:42 UTC |
Trower PaulPrincipal Accounting Officer
|
Tax withholdingCommon Stock | 272 | $74.21 | $20,185.12 |
DisclosureSEC source: 0001209191-19-002803 · doc4.xml · nonDerivative · entry 3 Trower Paul · CIK 0001642041 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,900 F2 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F3 · balance_after: This includes an aggregate of 4,797 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| January 07, 2019 Filed Jan 8, 2019 21:42 UTC |
Trower PaulPrincipal Accounting Officer
|
SaleCommon Stock | 9,187 | $75.00 | $689,025.00 |
DisclosureSEC source: 0001209191-19-002803 · doc4.xml · nonDerivative · entry 2 Trower Paul · CIK 0001642041 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,172 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. Read SEC document |
| January 07, 2019 Filed Jan 8, 2019 21:42 UTC |
Trower PaulPrincipal Accounting Officer
|
Exercise / conversionCommon Stock | 9,187 | $17.79 | $163,436.73 |
DisclosureSEC source: 0001209191-19-002803 · doc4.xml · nonDerivative · entry 1 Trower Paul · CIK 0001642041 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,359 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 07, 2019 Filed Jan 8, 2019 21:32 UTC |
Stein Steven HEVP & Chief Medical Officer
|
Tax withholdingCommon Stock | 847 | $74.21 | $62,855.87 |
DisclosureSEC source: 0001209191-19-002792 · doc4.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,773 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: Includes an aggregate of 5,416 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| January 07, 2019 Filed Jan 8, 2019 21:16 UTC |
Flannelly Barry PEVP & General Manager US
|
Tax withholdingCommon Stock | 896 | $74.21 | $66,492.16 |
DisclosureSEC source: 0001209191-19-002767 · doc4.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,658 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: Includes an aggregate of 5,416 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| January 07, 2019 Filed Jan 8, 2019 21:22 UTC |
Hoppenot HerveDirector · Chairman / CEO · President
|
Tax withholdingCommon Stock | 4,604 | $74.21 | $341,662.84 |
DisclosureSEC source: 0001209191-19-002773 · doc4.xml · nonDerivative · entry 1 Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,532 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: Includes an aggregate of 87,728 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| January 04, 2019 Filed Jan 8, 2019 21:46 UTC |
Wenqing YaoEVP, Head of Discovery Chem
|
GrantEmployee Stock Option (right to buy) · Derivative | 22,772 | $0.00 Strike: $72.27 | $0.00 |
DisclosureSEC source: 0001209191-19-002811 · doc4.xml · derivative · entry 4 Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,772 Underlying: Common Stock · 22,772 shares Expires 2029-01-03 F4 · derivative.exercise_date: Beginning January 4, 2019, options become exercisable in 37 installments, with the first 25.00% vesting on July 2, 2019 and the remainder vesting monthly over three years. Read SEC document |
| January 04, 2019 Filed Jan 8, 2019 21:37 UTC |
SWAIN PAULA JEVP, Human Resources
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $18.32 | $0.00 |
DisclosureSEC source: 0001209191-19-002796 · doc4.xml · derivative · entry 6 SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,782 Underlying: Common Stock · 30,000 shares Expires 2020-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Beginning February 9, 2013, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years. Read SEC document |
| January 04, 2019 Filed Jan 8, 2019 21:37 UTC |
SWAIN PAULA JEVP, Human Resources
|
GrantEmployee Stock Option (right to buy) · Derivative | 31,552 | $0.00 Strike: $72.27 | $0.00 |
DisclosureSEC source: 0001209191-19-002796 · doc4.xml · derivative · entry 5 SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,552 Underlying: Common Stock · 31,552 shares Expires 2029-01-03 F5 · derivative.exercise_date: Beginning January 4, 2019, options become exercisable in full on January 4, 2023. Read SEC document |
| January 04, 2019 Filed Jan 8, 2019 21:37 UTC |
SWAIN PAULA JEVP, Human Resources
|
GrantEmployee Stock Option (right to buy) · Derivative | 22,772 | $0.00 Strike: $72.27 | $0.00 |
DisclosureSEC source: 0001209191-19-002796 · doc4.xml · derivative · entry 4 SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,772 Underlying: Common Stock · 22,772 shares Expires 2029-01-03 F4 · derivative.exercise_date: Beginning January 4, 2019, options become exercisable in 37 installments, with the first 25.00% vesting on July 2, 2019 and the remainder vesting monthly over three years. Read SEC document |
| January 04, 2019 Filed Jan 8, 2019 21:37 UTC |
SWAIN PAULA JEVP, Human Resources
|
SaleCommon Stock | 30,000 | $70.00 | $2,100,000.00 |
DisclosureSEC source: 0001209191-19-002796 · doc4.xml · nonDerivative · entry 2 SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,324 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. Read SEC document |
| January 04, 2019 Filed Jan 8, 2019 21:37 UTC |
SWAIN PAULA JEVP, Human Resources
|
Exercise / conversionCommon Stock | 30,000 | $18.32 | $549,600.00 |
DisclosureSEC source: 0001209191-19-002796 · doc4.xml · nonDerivative · entry 1 SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,324 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 04, 2019 Filed Jan 8, 2019 21:42 UTC |
Trower PaulPrincipal Accounting Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 7,377 | $0.00 Strike: $72.27 | $0.00 |
DisclosureSEC source: 0001209191-19-002803 · doc4.xml · derivative · entry 5 Trower Paul · CIK 0001642041 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,377 Underlying: Common Stock · 7,377 shares Expires 2029-01-03 F5 · derivative.exercise_date: Beginning January 4, 2019, options become exercisable in full on January 4, 2023. Read SEC document |
| January 04, 2019 Filed Jan 8, 2019 21:42 UTC |
Trower PaulPrincipal Accounting Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 6,298 | $0.00 Strike: $72.27 | $0.00 |
DisclosureSEC source: 0001209191-19-002803 · doc4.xml · derivative · entry 4 Trower Paul · CIK 0001642041 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,298 Underlying: Common Stock · 6,298 shares Expires 2029-01-03 F4 · derivative.exercise_date: Beginning January 4, 2019, options become exercisable in 37 installments, with the first 25.00% vesting on July 2, 2019 and the remainder vesting monthly over three years. Read SEC document |
| January 04, 2019 Filed Jan 8, 2019 21:32 UTC |
Stein Steven HEVP & Chief Medical Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 22,772 | $0.00 Strike: $72.27 | $0.00 |
DisclosureSEC source: 0001209191-19-002792 · doc4.xml · derivative · entry 2 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,772 Underlying: Common Stock · 22,772 shares Expires 2029-01-03 F3 · derivative.exercise_date: Beginning January 4, 2019, options become exercisable in 37 installments, with the first 25.00% vesting on July 2, 2019 and the remainder vesting monthly over three years. Read SEC document |
| January 04, 2019 Filed Jan 8, 2019 21:28 UTC |
Pasquale Maria EEVP & General Counsel
|
GrantEmployee Stock Option (right to buy) · Derivative | 22,772 | $0.00 Strike: $72.27 | $0.00 |
DisclosureSEC source: 0001209191-19-002790 · doc4.xml · derivative · entry 1 Pasquale Maria E · CIK 0001736295 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,772 Underlying: Common Stock · 22,772 shares Expires 2029-01-03 F1 · derivative.exercise_date: Beginning January 4, 2019, options become exercisable in 37 installments, with the first 25.00% vesting on July 2, 2019 and the remainder vesting monthly over three years. Read SEC document |
| January 04, 2019 Filed Jan 8, 2019 21:25 UTC |
Iyengar Vijay KEVP GPS, BD, & Licensing
|
GrantEmployee Stock Option (right to buy) · Derivative | 31,552 | $0.00 Strike: $72.27 | $0.00 |
DisclosureSEC source: 0001209191-19-002783 · doc4.xml · derivative · entry 2 Iyengar Vijay K · CIK 0001670000 · EVP GPS, BD, & Licensing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,552 Underlying: Common Stock · 31,552 shares Expires 2029-01-03 F2 · derivative.exercise_date: Beginning January 4, 2019, options become exercisable in full on January 4, 2023. Read SEC document |
| January 04, 2019 Filed Jan 8, 2019 21:25 UTC |
Iyengar Vijay KEVP GPS, BD, & Licensing
|
GrantEmployee Stock Option (right to buy) · Derivative | 22,772 | $0.00 Strike: $72.27 | $0.00 |
DisclosureSEC source: 0001209191-19-002783 · doc4.xml · derivative · entry 1 Iyengar Vijay K · CIK 0001670000 · EVP GPS, BD, & Licensing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,772 Underlying: Common Stock · 22,772 shares Expires 2029-01-03 F1 · derivative.exercise_date: Beginning January 4, 2019, options become exercisable in 37 installments, with the first 25.00% vesting on July 2, 2019 and the remainder vesting monthly over three years. Read SEC document |
| January 04, 2019 Filed Jan 8, 2019 21:16 UTC |
Flannelly Barry PEVP & General Manager US
|
GrantEmployee Stock Option (right to buy) · Derivative | 63,105 | $0.00 Strike: $72.27 | $0.00 |
DisclosureSEC source: 0001209191-19-002767 · doc4.xml · derivative · entry 3 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,105 Underlying: Common Stock · 63,105 shares Expires 2029-01-03 F4 · derivative.exercise_date: Beginning January 4, 2019, options become exercisable in full on January 4, 2023. Read SEC document |
| January 04, 2019 Filed Jan 8, 2019 21:16 UTC |
Flannelly Barry PEVP & General Manager US
|
GrantEmployee Stock Option (right to buy) · Derivative | 22,772 | $0.00 Strike: $72.27 | $0.00 |
DisclosureSEC source: 0001209191-19-002767 · doc4.xml · derivative · entry 2 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,772 Underlying: Common Stock · 22,772 shares Expires 2029-01-03 F3 · derivative.exercise_date: Beginning January 4, 2019, options become exercisable in 37 installments, with the first 25.00% vesting on July 2, 2019 and the remainder vesting monthly over three years. Read SEC document |
| January 04, 2019 Filed Jan 8, 2019 21:22 UTC |
Hoppenot HerveDirector · Chairman / CEO · President
|
GrantEmployee Stock Option (right to buy) · Derivative | 88,558 | $0.00 Strike: $72.27 | $0.00 |
DisclosureSEC source: 0001209191-19-002773 · doc4.xml · derivative · entry 3 Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,558 Underlying: Common Stock · 88,558 shares Expires 2029-01-03 F4 · derivative.exercise_date: Beginning January 4, 2019, options become exercisable in 37 installments, with the first 25.00% vesting on July 2, 2019 and the remainder vesting monthly over three years. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 21:20 UTC |
Hoppenot HerveDirector · Chairman / CEO · President
|
Tax withholdingCommon Stock | 27,630 | $63.56 | $1,756,162.80 |
DisclosureSEC source: 0001209191-19-000921 · doc4.xml · nonDerivative · entry 1 Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,136 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: Includes an aggregate of 98,170 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| December 31, 2018 Filed Jan 2, 2019 21:10 UTC |
BAKER BROS. ADVISORS LPDirector · 10% owner
14159, L.P.Director · 10% owner
667, L.P.Director · 10% owner
Baker Bros. Advisors (GP) LLCDirector · 10% owner
Baker Brothers Life Sciences LPDirector · 10% owner
BAKER FELIXDirector · 10% owner
BAKER JULIANDirector · 10% owner
|
GrantCommon Stock | 298 | $63.59 | $18,949.82 |
DisclosureSEC source: 0001638599-19-000003 · doc4_5838.xml · nonDerivative · entry 6 BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner 14159, L.P. · CIK 0001551138 · Director · 10% owner 667, L.P. · CIK 0001551139 · Director · 10% owner Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner BAKER FELIX · CIK 0001087940 · Director · 10% owner BAKER JULIAN · CIK 0001087939 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 810,862 F4 · ownership.nature: 298 shares of common stock (the "Common Stock") issued to Julian C. Baker pursuant to the Issuer's Amended and Restated 2010 Stock Incentive Plan (the "Stock Incentive Plan") in lieu of director retainer fees of $19,000. The shares of Common Stock are fully vested. Julian C. Baker serves on the Issuer's Board of Directors (the "Board") as a representative of the Funds (as defined below). F5 · ownership.nature: Pursuant to the policies of Baker Bros. Advisors LP (the "Adviser"), Julian C. Baker does not have any right to the pecuniary interest in the Issuer's securities issued in lieu of director retainer fees and the Funds (as defined below) are entitled to an indirect proportionate pecuniary interest in the securities. 667, L.P. ("667"), Baker Brothers Life Sciences, L.P. ("Life Sciences") and 14159, L.P. ("14159", and together with 667, and Life Sciences, the "Funds") each owns an indirect proportionate pecuniary interest in the shares of Common Stock. Solely as a result of their ownership interest in the general partners of the general partners of the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock issued in lieu of director retainer fees (ie. no direct pecuniary interest). F8 · ownership.nature: As a result of Felix J. Baker's and Julian C. Baker's ownership interest in 14159 Capital (GP), LLC, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in 810,862 shares of common stock of the Issuer beneficially owned by 14159, a limited partnership of which the sole general partner is 14159 Capital, L.P., a limited partnership of which the sole general partner is 14159 Capital (GP), LLC, due to 14159 Capital, L.P.'s right to receive an allocation of a portion of the profits from 14159. Includes beneficial ownership of 3,156 shares issued pursuant to the Stock Incentive Plan in lieu of director retainer fees and 115,000 shares received previously from exercise of 115,000 stock options of the Issuer that were issued to Julian C. Baker in his capacity as a director of the Issuer, of which the fund may be deemed to own a portion. F9 · ownership.nature: The Adviser serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are Managing Members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. F10 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose. F11 · ownership.nature: The 298 shares are reported for each of the Funds as each has an indirect pecuniary interest. Read SEC document |
| December 31, 2018 Filed Jan 2, 2019 21:10 UTC |
BAKER BROS. ADVISORS LPDirector · 10% owner
14159, L.P.Director · 10% owner
667, L.P.Director · 10% owner
Baker Bros. Advisors (GP) LLCDirector · 10% owner
Baker Brothers Life Sciences LPDirector · 10% owner
BAKER FELIXDirector · 10% owner
BAKER JULIANDirector · 10% owner
|
GrantCommon Stock | 298 | $63.59 | $18,949.82 |
DisclosureSEC source: 0001638599-19-000003 · doc4_5838.xml · nonDerivative · entry 5 BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner 14159, L.P. · CIK 0001551138 · Director · 10% owner 667, L.P. · CIK 0001551139 · Director · 10% owner Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner BAKER FELIX · CIK 0001087940 · Director · 10% owner BAKER JULIAN · CIK 0001087939 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 29,268,793 F4 · ownership.nature: 298 shares of common stock (the "Common Stock") issued to Julian C. Baker pursuant to the Issuer's Amended and Restated 2010 Stock Incentive Plan (the "Stock Incentive Plan") in lieu of director retainer fees of $19,000. The shares of Common Stock are fully vested. Julian C. Baker serves on the Issuer's Board of Directors (the "Board") as a representative of the Funds (as defined below). F5 · ownership.nature: Pursuant to the policies of Baker Bros. Advisors LP (the "Adviser"), Julian C. Baker does not have any right to the pecuniary interest in the Issuer's securities issued in lieu of director retainer fees and the Funds (as defined below) are entitled to an indirect proportionate pecuniary interest in the securities. 667, L.P. ("667"), Baker Brothers Life Sciences, L.P. ("Life Sciences") and 14159, L.P. ("14159", and together with 667, and Life Sciences, the "Funds") each owns an indirect proportionate pecuniary interest in the shares of Common Stock. Solely as a result of their ownership interest in the general partners of the general partners of the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock issued in lieu of director retainer fees (ie. no direct pecuniary interest). F7 · ownership.nature: As a result of Felix J. Baker's and Julian C. Baker's ownership interest in Baker Brothers Life Sciences Capital (GP), LLC, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in 29,268,793 shares of common stock of the Issuer beneficially owned by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences. Includes beneficial ownership of 3,156 shares issued pursuant to the Stock Incentive Plan in lieu of director retainer fees and 115,000 shares received previously from exercise of 115,000 stock options of the Issuer that were issued to Julian C. Baker in his capacity as a director of the Issuer, of which the fund may be deemed to own a portion. F9 · ownership.nature: The Adviser serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are Managing Members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. F10 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose. F11 · ownership.nature: The 298 shares are reported for each of the Funds as each has an indirect pecuniary interest. Read SEC document |
| December 31, 2018 Filed Jan 2, 2019 21:10 UTC |
BAKER BROS. ADVISORS LPDirector · 10% owner
14159, L.P.Director · 10% owner
667, L.P.Director · 10% owner
Baker Bros. Advisors (GP) LLCDirector · 10% owner
Baker Brothers Life Sciences LPDirector · 10% owner
BAKER FELIXDirector · 10% owner
BAKER JULIANDirector · 10% owner
|
GrantCommon Stock | 298 | $63.59 | $18,949.82 |
DisclosureSEC source: 0001638599-19-000003 · doc4_5838.xml · nonDerivative · entry 4 BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner 14159, L.P. · CIK 0001551138 · Director · 10% owner 667, L.P. · CIK 0001551139 · Director · 10% owner Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner BAKER FELIX · CIK 0001087940 · Director · 10% owner BAKER JULIAN · CIK 0001087939 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 4,408,264 F4 · ownership.nature: 298 shares of common stock (the "Common Stock") issued to Julian C. Baker pursuant to the Issuer's Amended and Restated 2010 Stock Incentive Plan (the "Stock Incentive Plan") in lieu of director retainer fees of $19,000. The shares of Common Stock are fully vested. Julian C. Baker serves on the Issuer's Board of Directors (the "Board") as a representative of the Funds (as defined below). F5 · ownership.nature: Pursuant to the policies of Baker Bros. Advisors LP (the "Adviser"), Julian C. Baker does not have any right to the pecuniary interest in the Issuer's securities issued in lieu of director retainer fees and the Funds (as defined below) are entitled to an indirect proportionate pecuniary interest in the securities. 667, L.P. ("667"), Baker Brothers Life Sciences, L.P. ("Life Sciences") and 14159, L.P. ("14159", and together with 667, and Life Sciences, the "Funds") each owns an indirect proportionate pecuniary interest in the shares of Common Stock. Solely as a result of their ownership interest in the general partners of the general partners of the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock issued in lieu of director retainer fees (ie. no direct pecuniary interest). F6 · ownership.nature: As a result of Felix J. Baker's and Julian C. Baker's ownership interest in Baker Biotech Capital (GP), LLC, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in 4,408,264 shares of common stock of the Issuer beneficially owned by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP),LLC, due to Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667. Includes beneficial ownership of 3,156 shares issued pursuant to the Stock Incentive Plan in lieu of director retainer fees and 115,000 shares received previously from exercise of 115,000 stock options of the Issuer that were issued to Julian C. Baker in his capacity as a director of the Issuer, of which the fund may be deemed to own a portion. F9 · ownership.nature: The Adviser serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are Managing Members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. F10 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose. F11 · ownership.nature: The 298 shares are reported for each of the Funds as each has an indirect pecuniary interest. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 21:12 UTC |
FOUSE JACQUALYN ADirector
|
GrantCommon Stock | 196 | $63.59 | $12,463.64 |
DisclosureSEC source: 0001209191-19-000904 · doc4.xml · nonDerivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 712 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 21:08 UTC |
DIXON WENDY LDirector
|
GrantCommon Stock | 255 | $63.59 | $16,215.45 |
DisclosureSEC source: 0001209191-19-000889 · doc4.xml · nonDerivative · entry 1 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,199 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 21:05 UTC |
BROOKE PAUL ADirector
|
GrantCommon Stock | 373 | $63.59 | $23,719.07 |
DisclosureSEC source: 0001209191-19-000880 · doc4.xml · nonDerivative · entry 1 BROOKE PAUL A · CIK 0001175940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,929 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 21:02 UTC |
BIENAIME JEAN JACQUESDirector
|
GrantCommon Stock | 228 | $63.59 | $14,498.52 |
DisclosureSEC source: 0001209191-19-000858 · doc4.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,896 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 21:10 UTC |
Dhanak DashyantEVP & Chief Scientific Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 48,403 | $0.00 Strike: $65.42 | $0.00 |
DisclosureSEC source: 0001209191-18-062223 · doc4.xml · derivative · entry 2 Dhanak Dashyant · CIK 0001760682 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,403 Underlying: Common Stock · 48,403 shares Expires 2028-12-10 F2 · derivative.exercise_date: Beginning December 10, 2018, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 21:10 UTC |
Dhanak DashyantEVP & Chief Scientific Officer
|
GrantCommon Stock | 6,878 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-062223 · doc4.xml · nonDerivative · entry 1 Dhanak Dashyant · CIK 0001760682 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,878 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Dr. Dashyant Dhanak's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.